JP2022514799A5 - - Google Patents
Info
- Publication number
- JP2022514799A5 JP2022514799A5 JP2021543577A JP2021543577A JP2022514799A5 JP 2022514799 A5 JP2022514799 A5 JP 2022514799A5 JP 2021543577 A JP2021543577 A JP 2021543577A JP 2021543577 A JP2021543577 A JP 2021543577A JP 2022514799 A5 JP2022514799 A5 JP 2022514799A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- compound according
- pharmaceutical composition
- hydrogen
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1816369.1 | 2018-10-08 | ||
| GBGB1816369.1A GB201816369D0 (en) | 2018-10-08 | 2018-10-08 | Pharmaceutical compounds |
| PCT/EP2019/077118 WO2020074461A1 (en) | 2018-10-08 | 2019-10-07 | Tyk2 kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022514799A JP2022514799A (ja) | 2022-02-15 |
| JP2022514799A5 true JP2022514799A5 (enExample) | 2022-09-28 |
| JP7383030B2 JP7383030B2 (ja) | 2023-11-17 |
Family
ID=64397425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021543577A Active JP7383030B2 (ja) | 2018-10-08 | 2019-10-07 | Ｔｙｋ２キナーゼ阻害剤 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US12187716B2 (enExample) |
| EP (1) | EP3864009B1 (enExample) |
| JP (1) | JP7383030B2 (enExample) |
| KR (1) | KR102844196B1 (enExample) |
| CN (1) | CN113056456B (enExample) |
| AU (1) | AU2019359320B2 (enExample) |
| BR (1) | BR112021006424A2 (enExample) |
| CA (1) | CA3111049A1 (enExample) |
| DK (1) | DK3864009T3 (enExample) |
| ES (1) | ES3021420T3 (enExample) |
| FI (1) | FI3864009T3 (enExample) |
| GB (1) | GB201816369D0 (enExample) |
| IL (1) | IL281599B2 (enExample) |
| MX (1) | MX2021003929A (enExample) |
| PL (1) | PL3864009T3 (enExample) |
| PT (1) | PT3864009T (enExample) |
| SG (1) | SG11202102490TA (enExample) |
| WO (1) | WO2020074461A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202005114D0 (en) * | 2020-04-07 | 2020-05-20 | Sareum Ltd | Crystalline Forms of a Pharmaceutical Compound |
| EP4423086A1 (en) | 2021-10-25 | 2024-09-04 | Kymera Therapeutics, Inc. | Tyk2 degraders and uses thereof |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE794096A (fr) | 1972-08-07 | 1973-05-16 | Lepetit Spa | Oxazoles 2,4,5-trisubstitues et leur preparation |
| GB1497536A (en) | 1973-12-17 | 1978-01-12 | Lilly Industries Ltd | 2-acylaminooxazoles methods for their preparation and their use |
| DE19653355A1 (de) | 1996-12-20 | 1998-06-25 | Dresden Arzneimittel | Neue, antikonvulsiv wirkende Aminoimidazole und Verfahren zu ihrer Herstellung |
| GB0003154D0 (en) | 2000-02-12 | 2000-04-05 | Astrazeneca Uk Ltd | Novel compounds |
| NZ522696A (en) | 2000-06-28 | 2004-08-27 | Astrazeneca Ab | Substituted quinazoline derivatives and their use as inhibitors |
| MXPA03003868A (es) | 2000-10-30 | 2003-07-28 | Janssen Pharmaceutica Nv | Inhibidores de tripeptidil peptidasa. |
| EP1554269A1 (en) | 2002-07-09 | 2005-07-20 | Vertex Pharmaceuticals Incorporated | Imidazoles, oxazoles and thiazoles with protein kinase inhibiting activities |
| PL1684750T3 (pl) | 2003-10-23 | 2010-10-29 | Ab Science | 2-Aminoarylooksazole jako inhibitory kinazy tyrozynowej |
| GB0504753D0 (en) | 2005-03-08 | 2005-04-13 | Astrazeneca Ab | Chemical compounds |
| EP1932833B1 (en) | 2005-10-07 | 2012-08-01 | Kissei Pharmaceutical Co., Ltd. | Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same |
| ATE480525T1 (de) | 2006-05-12 | 2010-09-15 | Ab Science | Neues verfahren zur synthese von 2- aminooxazolverbindungen |
| US20090093452A1 (en) | 2006-08-24 | 2009-04-09 | Pfizer Inc. | Pyrrole, Thiophene, Furan, Imidazole, Oxazole, and Thiazole Derivatives |
| GB0709031D0 (en) | 2007-05-10 | 2007-06-20 | Sareum Ltd | Pharmaceutical compounds |
| EP2166846B1 (en) | 2007-06-20 | 2012-10-17 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
| EP2278969B1 (en) | 2008-04-21 | 2013-02-13 | Merck Sharp & Dohme Corp. | Inhibitors of Janus kinases |
| EP2299816B1 (en) | 2008-06-18 | 2013-11-13 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
| CA2730010A1 (en) | 2008-07-09 | 2010-01-14 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
| EP2166006A1 (en) | 2008-09-18 | 2010-03-24 | Dompe' S.P.A. | 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them |
| GB0820819D0 (en) | 2008-11-13 | 2008-12-24 | Sareum Ltd | Pharmaceutical compounds |
| JP2013522267A (ja) | 2010-03-17 | 2013-06-13 | エフ．ホフマン−ラ ロシュ アーゲー | イミダゾピリジン化合物、組成物、および使用法 |
| EP2588105A1 (en) | 2010-07-01 | 2013-05-08 | Cellzome Limited | Triazolopyridines as tyk2 inhibitors |
| WO2012021611A1 (en) | 2010-08-11 | 2012-02-16 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| WO2013055645A1 (en) | 2011-10-12 | 2013-04-18 | Array Biopharma Inc. | 5,7-substituted-imidazo[1,2-c]pyrimidines |
| GB201202027D0 (en) | 2012-02-06 | 2012-03-21 | Sareum Ltd | Pharmaceutical compounds |
| DK2634185T3 (en) * | 2012-03-02 | 2016-03-21 | Sareum Ltd | Tyk2 kinase inhibitors |
| KR101202026B1 (ko) | 2012-07-03 | 2012-11-16 | 민호현 | 황토 석부작 제조 방법 |
| AU2013341186B2 (en) | 2012-11-08 | 2017-03-30 | Bristol-Myers Squibb Company | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses |
| CN105793245B (zh) * | 2013-09-03 | 2018-03-20 | 萨勒姆有限公司 | 药物化合物 |
| JP6310767B2 (ja) | 2014-05-13 | 2018-04-11 | 日本電子株式会社 | 自動分析装置及びノズル洗浄方法 |
| NO2721710T3 (enExample) | 2014-08-21 | 2018-03-31 | ||
| GB201617871D0 (en) | 2016-10-21 | 2016-12-07 | Sareum Limited | Pharmaceutical compounds |
| GB202005114D0 (en) | 2020-04-07 | 2020-05-20 | Sareum Ltd | Crystalline Forms of a Pharmaceutical Compound |
-
2018
- 2018-10-08 GB GBGB1816369.1A patent/GB201816369D0/en not_active Ceased
-
2019
- 2019-10-07 WO PCT/EP2019/077118 patent/WO2020074461A1/en not_active Ceased
- 2019-10-07 ES ES19794095T patent/ES3021420T3/es active Active
- 2019-10-07 CA CA3111049A patent/CA3111049A1/en active Pending
- 2019-10-07 PL PL19794095.0T patent/PL3864009T3/pl unknown
- 2019-10-07 JP JP2021543577A patent/JP7383030B2/ja active Active
- 2019-10-07 KR KR1020217013504A patent/KR102844196B1/ko active Active
- 2019-10-07 DK DK19794095.0T patent/DK3864009T3/da active
- 2019-10-07 BR BR112021006424A patent/BR112021006424A2/pt unknown
- 2019-10-07 US US17/283,151 patent/US12187716B2/en active Active
- 2019-10-07 EP EP19794095.0A patent/EP3864009B1/en active Active
- 2019-10-07 FI FIEP19794095.0T patent/FI3864009T3/fi active
- 2019-10-07 SG SG11202102490TA patent/SG11202102490TA/en unknown
- 2019-10-07 MX MX2021003929A patent/MX2021003929A/es unknown
- 2019-10-07 CN CN201980066166.4A patent/CN113056456B/zh active Active
- 2019-10-07 IL IL281599A patent/IL281599B2/en unknown
- 2019-10-07 AU AU2019359320A patent/AU2019359320B2/en active Active
- 2019-10-07 PT PT197940950T patent/PT3864009T/pt unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013544887A5 (enExample) | ||
| JP2020033360A5 (enExample) | ||
| JP2017528507A5 (enExample) | ||
| JP2018513107A5 (enExample) | ||
| JP2014502641A5 (enExample) | ||
| JP2017528503A5 (enExample) | ||
| JP2012508734A5 (enExample) | ||
| JP2015528471A5 (enExample) | ||
| JP2021525729A5 (enExample) | ||
| JP2012502017A5 (enExample) | ||
| JP2013515074A5 (enExample) | ||
| RU2017114346A (ru) | АНТАГОНИСТЫ ИНТЕГРИНА ανβ6 | |
| JP2020502047A5 (enExample) | ||
| RU2017114352A (ru) | АНТАГОНИСТЫ ИНТЕГРИНА ανβ6 | |
| JP2015500223A5 (enExample) | ||
| JP2019516739A5 (enExample) | ||
| JP2015505564A5 (enExample) | ||
| JPWO2019160057A5 (enExample) | ||
| JP2018537513A5 (enExample) | ||
| JP2015510916A5 (enExample) | ||
| JP2023512664A5 (enExample) | ||
| JP2016537432A5 (enExample) | ||
| JP2021535147A5 (enExample) | ||
| PH12021550170A1 (en) | Pharmaceutical dosage form which can be adminitered orally and has modified release | |
| JP2018509426A5 (enExample) |